Laronidase solutionLaronidase is a polymorphic variant of the human enzyme ? liduronidase that is produced by recombinant DNA technology in a Chinese hamster ovary cell line. ?-l-iduronidase is a lysosomal hydrolase that catalyzes the hydrolysis of terminal ?-l-iduronic acid residues of dermatan sulfate and heparan sulfate.
It is indicated for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms. It has been shown to improve pulmonary function and walking capacity.
IV infusion; The recommended dosage regimen is 0.58 mg/kg of body weight administered once weekly as an intravenous (IV) infusion.
Paediatric: Safety and efficacy in 6 month to 18 year old is similar to adults Pregnancy: Category B Lactation: It is not known whether the drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when it is administered to a nursing woman. Elderly: Data not sufficient
Infusion reaction, Thrombocytopenia, Corneal opacity, Chest pain, Face edema, Gravitational edema, Injection site pain, Injection site reaction , Hyperbilirubinemia, Abscess, Upper respiratory tract infection, Hyperreflexia, Paresthesia, Rash, Hypotension, Poor venous access
Data not sufficient